Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV005027051 | SCV005659944 | uncertain significance | Renal coloboma syndrome; Focal segmental glomerulosclerosis 7 | 2024-01-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV005027051 | SCV005850336 | uncertain significance | Renal coloboma syndrome; Focal segmental glomerulosclerosis 7 | 2024-12-13 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 173 of the PAX2 protein (p.Pro173Ser). This variant is present in population databases (no rsID available, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with PAX2-related conditions. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |